# US 2010/0166703 A1 · Use of il-6/il-6 chimera in huntington's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166703 A1
- Document ID: US20100166703A1
- Status: Published application
- Kind: A1
- Application number: 12/717,305
- Filed: 2010-03-04
- Published: 2010-07-01
- Earliest claimed: 2000-09-14
- Assignees: Ares Trading S.A.
- Inventors: NICOLE DEGLON; PATRICK AEBISCHER; JEAN-CHARLES BENSADOUN
- Web page: https://patentgrep.com/patent/US20100166703A1

## CPC

- A61K 38/204: {IL-6}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.

## Claims

### Claim 1

A method for attenuating or ameliorating the symptoms of Huntington's disease, comprising administering to a patient in need thereof
1) an effective amount of an IL-6R/IL-6 chimera comprising
a) IL-6R having the sequence of residues 20-356 of SEQ ID NO:2;
b) IL-6 having the sequence of residues 360-543 of SEQ ID NO:2; and
c) optionally, a linker sequence between the sequences of a) and b), said linker sequence having a length of 1-18 residues;
or a functional derivative or salt of said chimera, said chimera being glycosylated at one or more sites, or
2) an effective amount of a cell expressing said chimera or an expression vector comprising a nucleic acid encoding said chimera.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said IL-6R, IL-6 and optional linker sequence is fused to an immunoglobulin (Ig).

### Claim 3 (depends on 1)

A method according to claim 1, wherein the functional derivative comprises at least one moiety attached to one or more functional groups which occur as one or more side chains on the amino acid residues.

### Claim 4 (depends on 1)

A method according to claim 1, wherein said administering step comprises administering a cell expressing said chimera.

### Claim 5 (depends on 1)

A method according to claim 1, wherein said administering step comprises administering an expression vector comprising the coding sequence of said chimera.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the vector is a lentiviral vector.